CompletedNCT00606177
Long-term aripiprazole or placebo after mania or a mixed episode in bipolarity
About this title
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Read the official source — NCT00606177Researchers compared Aripiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Aripiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
What did participation involve?
Depending on the group, the protocol specifies the study medication (aripiprazole) or a placebo (an inactive comparison treatment).
- Listed locations
- Hong Kong and 11 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 99
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China, Japan, South Korea, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00606177
- Official title
Show the full official title
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Get this study by email
Recruitment & locations
CompletedHong Kong, China · Chubu Region, Japan · Chugoku Region, Japan
9 more locations
- Hokkaido Region, Japan
- Hokuriku Region, Japan
- Kanto Region, Japan
- Kinki Region, Japan
- Kyushu Region, Japan
- Shikoku Region, Japan
- Tohoku Region, Japan
- Seoul, South Korea
- Taipei, Taiwan
Questions about this study
What did researchers investigate?
Researchers compared Aripiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
